Description: Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
Home Page: www.intervacc.se
Västertorpsvägen 135
Hägersten,
129 44
Sweden
Phone:
46 8 12 01 06 00
Officers
| Name | Title |
|---|---|
| Mr. Andreas Andersson | Pres & CEO |
| Mr. Andreas Johansson | Chief Financial Officer |
| Mr. Jan Persson | Chief Financial Officer |
| Mr. Patrik Hellberg | Chief Investment Officer |
| Dr. Andrew Waller | Chief Scientific Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0242 |
| Price-to-Sales TTM: | 125.8277 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |